Sculco E, Garzi G. A case of successful dupilumab treatment in allergic rhinitis and atopic dermatitis in patient with multiple food allergies, pollen and perennial sensitization. Series Clin Med Case Rep Rev. 2024;2(6):1-4.
Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4αR subunit. Blockade of IL-4/13 is effective in reducing Th2-oriented response including the release of proinflammatory cytokines, chemokines, and IgE. These mechanisms are mediators in the pathogenesis of atopic dermatitis (AD), food allergy, allergic rhinitis (AR) with and without polyposis, and asthma. We report the clinical case of a patient in whom the Th2-mediated inflammatory substrate is evident in comorbid allergic manifestations and shows a good response after treatment with dupilumab for moderate AD.
